Engineering and Construction of Pacemaker and Implantable Cardioverter-Defibrillator Leads

Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy

Volumn , Issue , 2007, Pages 161-200

  Russo, Andrea M ^a   Marchlinski, Francis E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 39749188646     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-2536-8.50009-1     Document Type: Chapter

References (203)

1. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996, 335:1933-1940.
2. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999, 341:1882-1890. the Multicenter Unsustained Tachycardia Trial Investigators.
3. Moss AJ, Zareba W, Hall J, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction (The Multicenter Automatic Defibrillator Implantation Trial II). N Engl J Med 2002, 346:877-883.
4. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near fatal ventricular arrhythmias. N Engl J Med 1997, 337:1576-1583. Antiarrhythmics Versus Implantable Defibrillator (AVID) Investigators.
5. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics Versus Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000, 21:2071-2078.
6. Mirowski M, Mower MM, Reid PR, Watkins L Implantable automatic defibrillators: Their potential in prevention of sudden coronary death. Ann N Y Acad Sci 1982, 382:371-380.
7. Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980, 303:322-324.
8. Reid PR, Mirowski M, Mower MM, et al. Clinical evaluation of the internal automatic cardioverter defibrillator in survivors of sudden cardiac death. Am J Cardiol 1983, 51:1608-1613.
9. Marchlinski FE, Flores BT, Buxton AE, et al. Automatic implantable cardioverter defibrillator: Efficacy, complicationas and device failures. Ann Intern Med 1986, 104:481.
10. Troup PJ, Chapman PD, Olinger GN, Kleinman LH The implanted defibrillator: Relation of defibrillating lead configuration and clinical variables to defibrillation threshold. J Am Coll Cardiol 1985, 6:1315-1321.
11. Mirowski M The automatic implantable cardioverter defibrillator: An overview. J Am Coll Cardiol 1985, 6:461-466.
12. Kelly PA, Cannom DS, Garan H, et al. The automatic implantable cardioverter defibrillator: Efficacy, complications and survival in patients with malignant ventricular arrhythmias. J Am Coll Cardiol 1988, 11:1278-1286.
13. Gartman DM, Bardy GH, Allen MD, et al. Short-term morbidity and mortality of implantation of automatic implantable cardioverter defibrillator. J Thorac Cardiovasc Surg 1990, 100:353-359.
14. Echt DS, Armstrong K, Schmidt P, et al. Clinical experience, complications and survival in 70 patients with the automatic implantable cardioverter defibrillator. Circulation 1985, 71:289-296.
15. Fromer M, Brachmann J, Block M, et al. Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter defibrillator: Results of a European multicenter study of 102 implants. Circulation 1992, 86:363-374.
16. Saksena S Defibrillation threshold and perioperative mortality associated with either endocardial and epicardial defibrillation lead systems. The PCD Investigators and participating institutions. PACE 1993, 16:202-207.
17. Brady PA, Friedman PA, Trusty JM, et al. High failure rate of epicardial implantable cardioverter defibrillator lead: Implications for long-term follow-up of patients with an implantable cardioverter defibrillator. J Am Coll Cardiol 1998, 31:616-622.
18. Almassi GH, Olinger GN, Wetherbee JN, Fehl G Long-term complications of implantable cardioverter defibrillator lead systems. Ann Thorac Surg 1993, 55:888-892.
19. Korte T, Jung W, Spehl S, et al. Incidence of ICD lead related complications during long-term follow-up: Comparison of epicardial and endocardial electrode systems. PACE 1995, 18:2053-2061.
20. Mattke S, Muller D, Markewitz A, et al. Failures of epicardial and transvenous leads for implantable cardioverter defibrilators. Am Heart J 1995, 130:1040-1044.
21. Chevalier P, Mancada E, Canu G, et al. Symptomatic pericardial disease associated with patch electrodes of automatic implantable cardioverter defibrillator: An underestimated complication?. PACE 1996, 19:2150-2152.
22. Stambler BS, Wood MA, Damiano RJ, et al. Sensing/pacing lead complications with a newer generation implantable cardioverter defibrillator: Worldwide experience from the Guardian ATP 4210 clinical trial. J Am Coll Cardiol 1994, 23:123-132.
23. Daoud EG, Kirsh MM, Bolling SF, et al. Incidence, presentation, diagnosis, and management of malfunctioning implantable cardioverter defibrillator rate sensing leads. Am Heart J 1994, 128:892-895.
24. Grimm W, Flores BF, Marchlinski FE Complications of implantable cardioverter defibrillator therapy: Follow-up of 241 patients. PACE 1993, 16:218-222.
25. Sgarbossa EB, Shewchik J, Pinski SL Performance of implantable defibrillator pacing/sensing lead adapters. PACE 1996, 19:811-814.
26. Saksena S, Poczobutt-Johanos M, Castle LW, et al. Long-term multicenter experience with second generation implantable pacemaker defibrillator in patients with malignant ventricular tachyarrhythmias. J Am Coll Cardiol 1992, 19:490-499. for the Guardian Multicenter Investigators Group.
27. Kastor JS Michel Mirowski and the automatic implantable defibrillator. Am J Cardiol 1989, 63:1121-1126.
28. Mirowski M, Mower MM, Gott VL, Brawley RK Feasibility and effectiveness of low energy catheter defibrillation in man. Circulation 1973, 47:79-85.
29. Zipes DP, Jackman WM, Heger JJ, et al. Clinical transvenous cardioversion of recurrent life-threatening tachyarrhythmias: Low energy synchronized cardioversion of ventricular tachycardia and termination of ventricular fibrillation in patients using a catheter electrode. Am Heart J 1982, 103:789-794.
30. Zipes DP, Roberts D Results of the international study of the implantable pacemaker cardioverter defibrillator: A comparison of epicardial and endocardial lead systems. Circulation 1995, 92:59-65. for the Pacemaker Cardioverter-Defibrillator Investigators.
31. Trappe HJ, Fieguth HG, Pfitzner P, et al. Epicardial and non-thoracotomy lead systems combined with a cardioverter defibrillator. PACE 1995, 18:127-132.
32. Bocker D, Block M, Isbruch F, et al. Do patients with an implantable defibrillator live longer?. J Am Coll Cardiol 1993, 21:1638-1644.
33. Bardy GH, Hofer B, Johnson G, et al. Implantable transvenous cardioverter defibrillators. Circulation 1993, 87:1152-1168.
34. Hauser RG, Kurschinski DT, McVeigh K, et al. Clinical results with nonthoracotomy ICD systems. PACE 1993, 16:141-148.
35. Saksena S, An H Clinical efficacy of dual electrode systems for endocardial cardioversion of ventricular tachycardia: A prospective randomized crossover trial. Am Heart J 1990, 119:15-22.
36. Winkle RA, Bach SM, Mead RH, et al. Comparison of defibrillation efficacy in humans using a new catheter and superior vena cava spring left ventricular patch electrode. J Am Coll Cardiol 1988, 11:365-370.
37. Saksena S, Luceri R, Krol RB, et al. Endocardial pacing, cardioversion and defibrillation using a braided endocardial lead system. Am J Cardiol 1993, 71:834-841.
38. Hammel D, Block M, Borggrefe M, et al. Implantation of a cardioverter/defibrillator in the subpectoral region combined with a nonthoracotomy lead system. PACE 1992, 15:367-368.
39. Thakur RK, Ip JH, Mehta D, et al. Subpectoral implantation of ICD generators: Long-term follow-up. PACE 1995, 18:159-162.
40. Gregoratos G, Cheitlin MD, Conill A, et al. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelyines (Committee on Pacemaker Implantation). J Am Coll Cardiol 1998, 31:1175-1209.
41. Gradaus R, Breithardt G, Bocker D ICD leads: Design and chronic dysfunctions. PACE 2003, 26:649-657.
42. Accorti PR Leads technology. Implantable Cardioverter Defibrillator 1994, Futura, Armonk NY. I. Singer (Ed.).
43. Yabe S, Smith WM, Daubert JP, et al. Conduction disturbances caused by high current density electric fields. Circ Res 1990, 66:1190-1203.
44. Callans DJ, Swarna US, Schwartzman D, et al. Postshock sensing performance in transvenous defibrillation lead systems: Analysis of detection and redetection of ventricular fibrillation. J Cardiovasc Electrophysiol 1995, 6:604-612.
45. Mond H, Stokes K The electrode-tissue interface: The revolutionary role of steroid elution. PACE 1992, 15:95-107.
46. Stamato N, O'Toole MF, Fetter JG, Enger EL The safety and efficacy of chronic ventricular pacing at 1.6 volts using a steroid eluting lead. PACE 1992, 15:248-251.
47. Mond H, Stokes K, Helland J, et al. The porous titanium steroid eluting electrode: A double blind study assessing the stimulation threshold effects of steroid. PACE 1988, 11:214-219.
48. Kruse M Long-term performance of endocardial leads with steroid-eluting electrodes. PACE 1986, 9:1217-1219.
49. Radovsky AS, van Vleet JF, Stokes KB, Tacker WA Paired comparisons of steroid-eluting and nonsteriod endocardial pacemaker leads in dogs: Electrical performance and morphologic alterations. PACE 1988, 11:1085-1094.
50. Schuchert A, Hopf M, Kuck KH, Bleifeld W Chronic ventricular electrograms: Do steroid-eluting leads differ from conventional leads?. PACE 1990, 13:1879-1882.
51. Leitch JW, Yee R, Klein GJ, et al. Correclation between the ventricular electrogram amplitude in sinus rhythm and in ventricular fibrillation. PACE 1990, 13:1105-1109.
52. Almeida HF, Buckingham TA Inappropriate implantable cardioverter defibrillator shocks secondary to sensing lead failure: Utility of stored electrograms. PACE 1993, 16:407-410.
53. Sperry RE, Ellenbogen KA, Wood MA, et al. Failure of a second and third generation implantable cardioverter defibrillator to sense ventricular tachycardia: Implications for fixed-gain sensing devices. PACE 1992, 15:749-755.
54. Callans DJ, Hook BG, Kleiman RB, et al. Unique sensing errors in third-generation implantable cardioverter defibrillators. J Am Coll Cardiol 1993, 22:1135-1140.
55. Epstein AE, Kay GN, Plumb VJ, et al. Gross and microscopic pathological changes associated with nonthoracotomy implantable defibrillator leads. Circulation 1998, 98:1517-1524.
56. Epstein A, Anderson P, Kay GN, et al. Gross and microscopic changes associated with a nonthoracotomy implantable cardioverter defibrillators. PACE 1992, 15:382-386.
57. Hauser R, Hayes D, Parsonnet V, et al. Feasibility and initial results of an Internet-based pacemaker and ICD pulse generator and lead registry. PACE 2001, 24:82-87.
58. Jung W, Manz M, Moosdorf R, Luderitz B Failure of an implantable cardioverter defibrillator to redetect ventricular fibrillation in patients with a nonthoracotomy lead system. Circulation 1992, 86:1217-1222.
59. Natale A, Sra J, Axtell K, et al. Undetected ventricular fibrillation in transvenous implantable cardioverter defibrillators: Prosepective comparison of different lead system-device combinations. Circulation 1996, 93:91-98.
60. Berul CI, Callans DJ, Schwartzman DS, et al. Comparison of initial detection and redetection of ventricular fibrillation in a transvenous defibrillator system with automatic gain control. J Am Coll Cardiol 1995, 25:431-436.
61. Goldberger JJ, Horvath G, Donovan D, et al. Detection of ventricular fibrillation by transvenous defibrillating leads: Integrated versus dedicated bipolar sensing. J Cardiovasc Electrophysiol 1998, 9:677-688.
62. Gold MR, Shorofsky SR Transvenous defibrillation lead systems. J Cardiovasc Electrophysiol 1996, 7:570-580.
63. Gottlieb CD, Schwartzman DS, Callans DJ, et al. Effects of high and low shock energies on sinus electrograms recorded via integrated and true bipolar nonthoracotomy lead systems. J Cardiovasc Electrophysiol 1996, 7:189-196.
64. Ellenbogen KA, Wood MA, Shepard RK, et al. Detection and management of an implantable cardioverter defibrillator lead failure: Incidence and clinical implications. J Am Coll Cardiol 2003, 41:73-80.
65. Nelson RS, Gilman BL, Shapland JE, Lehmann MH Leads for the ICD. Implantable Cardioverter Defibrillator Therapy 1996, Kluwer Academic, Norwell, Mass. M.W. Kroll, M.H. Lehmann (Eds.).
66. Hayes DL, Graham KJ, Irwin M, et al. A multicenter experience with a bipolar tined polyurethane ventricular lead. PACE 1992, 15:1033-1039.
67. Fotuhi P, Alt E, Callihan R, et al. Endocardial carbon braid electrodes: New approach to lowering defibrillation thresholds. PACE 1993, 16:1919A.
68. Alt E, Theres H, Heinz M, et al. A new approach towards defibrillation electrodes: Highly conductive isotropic carbon fibers. PACE 1991, 14:1923-1928.
69. Jacobs DM, Fink AS, Miller RP, et al. Anatomical and morphological evaluation of pacemaker lead compression. PACE 1993, 16:434-444.
70. Magney JE, Flynn DM, Parsons JA, et al. Anatomical mechnaisms explaining damage to pacemaker leads, defibrillator leads, and failure of central venous catheters adjacent to the sternoclavicular joint. PACE 1993, 16:445-457.
71. Doring J, Flink R The impact of pending technologies on a universal connector standard. PACE 1986, 9:1186-1190.
72. Schaumann A, von zur Muhlen F, Gonska BD, Kreuzer H Enhanced detection criteria in implantable cardioverter-defibrillators to avoid inappropriate therapy. Am J Cardiol 1996, 78:42-50.
73. Butter C, Auricchio A, Schwarz T, et al. Clinical evaluation of a prototype passive fixation dual chamber single pass lead for dual chamber ICD systems. PACE 1999, 22:169-173.
74. Saksena S, DeGroot P, Krol RB, et al. Low energy endocardial defibrillation using an axillary or a pectoral thoracic electrode location. Circulation 1993, 88:2655-2660.
75. Higgins SL, Alexander DC, Kuypers CJ, Brewster SA The subcutaneous array: A new lead adjunct for the transvenous ICD to lower defibrillation thresholds. PACE 1995, 18:1540-1548.
76. Yee R, Klein GJ, Leitch JW, et al. A permanent transvenous lead system for an implantable pacemaker cardioverter defibrillator: Nonthoracotomy approach to implantation. Circulation 1992, 85:196-204.
77. Venditti FJ, Martin DT, Vassolas G, Bowen S Rise in chronic defibrillation thresholds in nonthroacotomy implantable defibrillators. Circulation 1994, 89:216-223.
78. Strickberger SA, Hummel JD, Horwood LE, et al. Effect of shock polarity on ventricular defibrillation threshold using a transvenous lead system. J Am Coll Cardiol 1994, 24:1069-1072.
79. Natale A, Sra J, Axtell K, et al. Preliminary experience with a hybrid nonthoracotomy defibrillating system that includes a biphasic device: Comparison with a standard monophasic device using the same lead system. J Am Coll Cardiol 1994, 24:406-412.
80. Bardy GH, Ivey TD, Allen MD, et al. A prospective randomized evaluation of biphasic versus monophasic waveform pulses on defibrillation efficacy in humans. J Am Coll Cardiol 1989, 14:728-733.
81. Block M, Hammel D, Bocker D, et al. A prospective randomized cross-over comparison of mono- and biphasic defibrillation using nonthoracotomy lead configurations in humans. J Cardiovasc Electrophysiol 1994, 5:581-590.
82. Natale A, Sra J, Krum D, et al. Comparsion of biphasic and monophasic pulses: Does the advantage of biphasic shocks depend on the waveshape?. PACE 1995, 18:1354-1361.
83. Saksena S, An H, Mehara R, et al. Prospective comparison of biphasic and monophasic shocks for implantable cardioverter defibrillators using endocardial leads. Am J Cardiol 1992, 70:304-310.
84. Saksena S, Scott SE, Accorti PR, et al. Efficacy and safety of monophasic and biphasic waveform shocks using a braided endocardial defibrillation lead system. Am Heart J 1990, 20:1342-1347.
85. Neuzner J, Pitschner HF, Huth C, Schlepper M Effect of biphasic waveform pulse on endocardial defibrillation efficacy in humans. PACE 1994, 17:207-212.
86. Bardy GH, Johnson G, Poole JE, et al. A simplified, single-lead unipolar transvenous cardioversion defibrillation system. Circulation 1993, 88:543-547.
87. Mattke S, Fiek M, Markewitz A, et al. Comparison of a unipolar defibrillation system with a dual lead system using an enlarged defibrillation anode. PACE 1996, 19:2083-2088.
88. Lang DJ, Heil JE, Hahn SJ, et al. Implantable cardioverter defibrillator lead technology: Improved performance and lower defibrillation thresholds. PACE 1995, 18:548-559.
89. Niebauer MJ, Yamanouchi Y, Hills D, et al. Voltage dependence of ICD lead polarization and the effect of iridium oxide coating. PACE 2000, 23:818-823.
90. Niebauer MJ, Wilkoff B, Yamanouchi Y, et al. Iridium oxide-coated defibrillation electrode: Reduced shock polarization and improved defibrillation efficacy. Circulation 1997, 96:3732-3736.
91. Gradaus R, Bocker D, Dorszewski A, et al. Fractally coated defibrillation electrodes: Is an improvement in defibrillation threshold possible?. Europace 2000, 2:154-159.
92. Peters RW, Foster AH, Shorofsky SR, et al. Spurious discharges due to late insulation break in endocardial sensing leads for cardioverter defibrillators. PACE 1995, 18:478-481.
93. Kron J, Herre J, Renfroe EG, et al. Lead and device-related complications in the Antiarrhythmics Versus Implantable Defibrillators Trial. Am Heart J 2001, 141:92-98. the AVID Investigators.
94. Degeratu FT, Khalighi K, Peters RW, et al. Sensing lead failure in implantable defibrillators: A comparison of two commonly used leads. J Cardiovasc Electrophysiol 2000, 11:21-24.
95. Gold MR, Peters RW, Johnson JW, Shorofsky SR Complications associated with pctoral implantation of cardioverter defibrillators. World-Wide Jewel Investigators. PACE 1997, 20:208-211.
96. Grimm W, Menz J, Hoffmann J, et al. Complications of third-generation implantable cardioverter defibrillator therapy. PACE 1999, 22:206-211.
97. Gupta A, Zegel HG, Dravid VS, et al. Value of radiography in diagnosing complications of cardioverter defibrillators implanted without thoracotomy in 437 patients. Am J Radiol 1997, 168:105-108.
98. Mehta D, Nayak HM, Signson M, et al. Late complications in patients with pectoral defibrillator implants with transvenous defibrillator lead systems: High incidence of insulation breakdown. PACE 1998, 21:1893-1900.
99. Dorwarth U, Frey B, Dugas M, et al. Transvenous defibrillatin leads: High incidence of failure during long-term follow-up. J Cardiovasc Electrophysiol 2003, 14:38-43.
100. Schwartzman D, Nallamouthu N, Callans DJ, et al. Postoperative lead-related complications in patients with nonthoracotomy defibrillator lead systems. J Am Coll Cardiol 1995, 26:776-786.
101. Brooks R, Garan H, Torchiana D, et al. Determinants of successful nonthoracotomy cardioverter defibrillator implantation: Experience in 101 patients using two different lead systems. J Am Coll Cardiol 1993, 22:1835-1842m.
102. Zipes DP, Roberts D Results of the international study of the implantable pacemaker cardioverter defibrillator: Intention-to-treat comparison of lnical outcomes. Circulation 1995, 92:59-65.
103. Raviele A, Gasparini G Italian multicenter clinical experience with endocardial defibrillation: Acute and long-term results in 307 patients. PACE 1995, 18:599-608. for the Italian Endotak Investigator Group.
104. Jones GK, Bardy GH, Kudenchuk PJ, et al. Mechanical complications after implantation of multiple lead nonthoracotomy defibrillator system: Implications for management and future system design. Am Heart J 1995, 130:327-333.
105. Lawton JS, Wood MA, Gilligan DM, et al. Implantable transvenous cardioverter defibrillator leads: The dark side. PACE 1996, 19:1273-1278.
106. Tullo NG, Saksena S, Krol RB, et al. Management of complications associated with a first-generation endocardial defibrillation lead system for implantable cardioverter defibrillators. Am J Cardiol 1990, 66:411-415.
107. Mahapatra S, Homound MK, Wang PJ, et al. Durability of repaired sensing leads equivalent to that of new leads in implantable cardioverter defibrillator patients with sensing abnormalities. PACE 2003, 26:2225-2229.
108. Sra JS, Natale A, Axtell K, et al. Experience with two different nonthoracotomy systems for implantable defibrillators in 170 patients. PACE 1994, 17:1741-1750.
109. Fahy GJ, Kleman JM, Wilkoff BL, et al. Low incidence of lead related complications associated with nonthoracotomy implantable cardioverter defibrillator systems. PACE 1995, 18:172-178.
110. Roelke M, O'Nunain SS, Osswald S, et al. Subclavian crush syndrome complicationg transvenous caredioverter defibrillator systems. PACE 1995, 18:973-979.
111. Gallik DKM, Ben-zur UM, Gross JN, Furman S Lead fracture in cephalic versus subclavian approach with transvenous implantable cardioverter defibrillator systems. PACE 1996, 19:1089-1094.
112. Hauser RG, Cannom D, Hayes DL, et al. Long-term structural failure of coaxial polyurethane implantable cardioverter defibrillator leads. PACE 2002, 25:879-882.
113. Peralta AO, John RM, Martin DT, Venditti FJ Long term performance of the Endotak C defibrillator lead [abstract]. Circulation 1998, 98:1-787.
114. Moore SL, Maloney JD, Edel TB, et al. Implantable cardioverter defibrillator implanted by nonthoracotomy approach: Initial clinical experience with the redesigned transvenous lead system. PACE 1991, 14:1865-1869.
115. Lawton JS, Ellenbogen KA, Wood MA, et al. Sensing lead-related complications in patients with transvenous implantable cardioverter defibrillators. Am J Cardiol 1996, 78:647-651.
116. Mera F, Delurgio DB, Langberg JJ, et al. Transvenous cardioverter defibrillator lead malfunction due to terminal connector damage in pectoral implants. PACE 1999, 22:1797-1801.
117. Block M, Hammel D, Isbruch F, et al. Results and realistic expectations with transvenous lead systems. PACE 1992, 15:665-670.
118. Schwartzman D, Nallamothu N, Callans DJ, et al. Postoperative lead-related complications in patients with nonthoractomy defibrillation lead systems. J Am Coll Cardiol 1995, 26:776-786.
119. Pratt TR, Pulling CC, Stanton MS Prospective postmarket device studies versus returned product analysis as a predictor of system survival. PACE 2000, 23:1150-1155.
120. Gras D, Leclereq C, Tang AS, et al. Cardiac resynchronization therapy in advanced heart failure: The multicenter InSync clinical study. Eur J Heart Fail 2002, 4:311-320.
121. Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimized cardiac resychronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Card 2002, 39:2026-2033. Pacing Therapies in Congestive Heart Failure (PATH-CHF) Study Group.
122. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001, 344:873-880. the Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators.
123. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: Results from the Multisite stimulation in caredioomyopathy (MUSTIC) study. J Am Coll Card 2002, 40:111-118.
124. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002, 346:1845-1853. the MIRACLE Study Group Multicenter InSync Randomized Clinical Evaluation.
125. Blanc JJ, Etienne Y, Giloard M, et al. Evaluation of different ventricular pacing sites in patients with severe heart failure: Results of an acute hemodynamic study. Circulation 1997, 96:3273-3277.
126. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. JAMA 2003, 289:2685-2694. the Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators.
127. Bristow MR, Saxon LA, Boehmeer J, et al. N Engl J Med 2004, 350:2140-2150. the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators.
128. Rossillo A, Verma A, Saad EB, et al. Impact of coronary sinus lead position on biventricular pacing: Mortality and echocar-diographic evaluation during long-term follow-up. J Cardiovasc Electrophysiol 2004, 15:1120-1125.
129. Butter C, Auricchio A, Stellbrink C, et al. Should stimulation site be tailored in the individual heart failure patient?. Am J Cardiol 2000, 86:144K-151K.
130. Purerfellner H, Nesser HJ, Winter S, et al. Transvenous left venticular lead implantation with the EASYTRAK lead system: The European experience. Am J Cardiol 2000, 86:157K-164K. for the EASYTRAK Clinical Investigation Study Group and the European EASYTRAK Registry.
131. Sack S, Heinzel F, Dagres N, et al. Stimulation of the left ventricle through the coronary sinus with a newly developed "over the wire" lead system: Early experiences with lead handling and positioning. Europace 2001, 3:317-323.
132. Achtelik M, Bocchiardo M, Trappe HJ, et al. Performance of a new steroid-eluting coronary sinus lead designed for lefter ventricular pacing. PACE 2000, 23:1741-1743. on behalf of the Ventak CHF/Contak CD Clinical Investigation Study Group.
133. Kantharia BK, Padder FA, Pennington JC, et al. Feasibility, safety, and determinants of extraction time of percutaneous extraction of endocardial implantable cardioverter defibrillator leads by intravascular countertraction method. Am J Cardiol 2000, 85:593-597.
134. Saad EB, Saliba WI, Schweikert RA, et al. Nonthoracotomy implantable defibrillator lead extraction: Results and comparison with extraction of pacemaker leads. Pacing Clin Electrophysiol 2003, 26:1944-1950.
135. Parsonnet V, Roelke M, Trivedi A, et al. Laser extraction of entrapped leads. PACE 2001, 24:329-332.
136. Morris MM, KenKnight BH, Warren JA, Lang DJ A preview of implantable cardioverter derfibrillator systems in the next millennium: An integrative cardiac rhythm management approach. Am J Cardiol 1999, 83:48D-54D.
137. Bardy GH, Cappato R, Smith WM, et al. The totally subcutaneous ICD system (the S-ICD) [abstract]. PACE 2002, 24:578.
138. Mond HG Unipolar versus bipolar pacing: Poles apart. PACE 1991, 14:1411.
139. Wiegand UK, Bode F, Bonnemeier H, et al. Incidence and predictors of pacemaker dysfunction with unipolar ventricular lead configuration: Can we identify patients who benefit from bipolar electrodes?. PACE 2001, 24:1383-1388.
140. Breivik K, Ohm OJ, Engedal H Long-term comparison of unipolar and bipolar pacing and sensing, using a new multipro-grammable pacemaker system. PACE 1983, 6:592-600.
141. Secemsky SI, Hauser RG, Denes P, Edwards LM Unipolar sensing abnormalities: Incidence and clinical significance of skeletal muscle interference and undersensing in 228 patients. PACE 1982, 5:10-19.
142. Echeverria HJ, Luceri RM, Thurber RJ, Castellanos A Myopotential inhibition of unipolar AV sequential (DVI) pacemaker. PACE 1982, 5:20-22.
143. Zimmern SH, Clark MF, Austin WK, et al. Characteristics and clinical effects of myopotential signals in a unipolar DDD pacemaker population. PACE 1986, 9:1019.
144. Smyth NP, Tarjan PP, Chernoff E, Baker N The significance of electrode surface area and stimulation thresholds in permanent cardiac pacing. J Thorac Cardiovasc Surg 1976, 71:559-565.
145. Furman S, Garvey J, Hurzeler P Pulse duration variation and electrode size as factors in pacemaker longevity. J Thorac Cardiovasc Surg 1975, 69:382-389.
146. Barold SS, Ong LS, Heinle RA Stimulation and sensing thresholds for cardiac pacing: Electrophysiologic and technical aspects. Prog Cardiovasc Dis 1981, 24:1-24.
147. Mond H, Holley L, Hirshorn M The high impedance dish electrode: Clinical experience with a new tined lead. PACE 1982, 5:529-534.
148. 2) on steroid-eluting leads. PACE 1991, 14:2098-2104.
149. Ellenbogen KA, Wood MA, Gilliagan DM, et al. Steroid-eluting high-impedance pacing leads decrease short and long-term current drain: Results from a multicenter clinical trial. PACE 1999, 22:39-48. the CapSure Z Investigators.
150. Moracchini PV, Cornacchia D, Bernasconi M, et al. High impedance low energy pacing leads: Long-term results with a very small surface area, steroid-eluting lead compared to three conventional electrodes. PACE 1999, 22:326-334.
151. Deshmukh P, Casavant D, Anderson K, Romanyshyn M Stable electrical performance of high efficiency pacing leads having small surface, steroid-eluting pacing electrodes. PACE 1999, 22:1599-1603.
152. Berger T, Roithinger FX, Antretter H, et al. The influence of high versus normal impedance ventricular leads on pacemaker generator longevity. PACE 2003, 26:2116-2120.
153. Scherer M, Ezziddin K, Klesius A, et al. Extension of generator longevity by use of high impedance ventricular leads. PACE 2001, 24:206-211.
154. Mond HG Engineering and clinical aspects of pacing leads. Clincial Cardiac Pacing and Defibrillation 2000, WB Saunders, Philadelphia. 2nd ed. K. Ellenbogen, G. Kay, B. Wilkoff (Eds.).
155. Luria D, Gurevitz O, Bar Lev D, et al. Use of automatic threshold tracking function with non-low polarization leads. PACE 2004, 27:453-459.
156. Amundson DC, McArthur W, Mosharrafa M The porous endocardial electrode. PACE 1979, 2:40-50.
157. Hirshorn MS, Holley LK, Skalsky M, et al. Characteristics of advanced porous and textured surface pacemaker electrodes. PACE 1983, 6:525-536.
158. Djordjevic M, Stojanov P, Velimirovic D Target lead: Low threshold electrode. PACE 1986, 9:1206.
159. Mond H, Hua W, Wang CC Atrial pacing leads: The clinical contribution of steroid elution. PACE 1995, 18:1601.
160. Parsonnet V, Villaneuva A, Driller J, Bernstein AD Corrosion of pacemaker electrodes. PACE 1981, 4:289-296.
161. Elmqvist H, Schueller H, Richter G The carbon tip electrode. PACE 1983, 6:436-439.
162. Mugica J, Henry L, Attuel P, et al. Clinical experience with 910 carbon tip leads: Comparison with polished platinum leads. PACE 1986, 9:1230-1238.
163. Gargeroglio B, Inguaggiato B, Chinaglia B, Cerise O Initial results with an activated carbon tip electrode. PACE 1983, 6:440-448.
164. Pioger G, Ripart A Clinical results of low energy unipolar or bipolar activated carbon tip leads. PACE 1986, 9:1243-1248.
165. Mond HG, Grenz D Implantable transvenous pacing leads: The shape of things to come. PACE 2004, 27:887-893.
166. Breivik K, Danilovic D, Ohm OJ, et al. Clinical evaluation of thin bipolar pacing lead. PACE 1997, 20:637-646.
167. Crossley GH Cardiac pacing leads. Cardiol Clin 2000, 18:95-112.
168. Scheuer-Lesser M, Irnich W, Kreuzer J Polyurethane leads: Facts and controversy. PACE 1983, 6:454-458.
169. Byrd CL, McArthur W, Stokes K, et al. Implant experience with unipolar polyurethane pacing leads. PACE 1983, 6:868-882.
170. Woscoboinik JR, Maloney JD, Helguera ME, et al. Pacing lead survival: Performance of different models. PACE 1992, 15:1991-1995.
171. Hayes DL, Graham KJ, Irwin M, et al. A multicenter experience with a bipolar tined polyurethane ventricular lead. PACE 1992, 15:1033-1039.
172. Sweesy MW, Forney CC, Hayes DL, et al. Evaluation of an inline bipolar polyurethane ventricular pacing lead. PACE 1992, 15:1982-1985.
173. Hayes DL, Graham KJ, Irwin M, et al. Multicenter experience with a bipolar tined polyurethane ventricular lead. PACE 1995, 18:999-1004.
174. Van Beek GJ, Den Dulk K, Lindemans FW, et al. Detection of insulation failure by gradual reduction in noninvasively measured electrogram amplitudes. PACE 1986, 9:772-775.
175. Pirzada FA, Seltzer JP, Blair-Saletin D, Killian M Five-year performance of the Medtronic 6971 polyurethane endocardial electrode. PACE 1986, 9:1173-1180.
176. Stokes KB, Church T Ten-year experience with implanted polyurethane lead insulation. PACE 1986, 9:1160-1164.
177. Antonelli D, Rosenfeld T, Freedberg NA, et al. Insulation lead failure: Is it a matter of insulation coating, venous approach, or both?. PACE 1998, 21:418-421.
178. Philips R, Frey M, Martin RO Long-term performance of polyurethane pacing leads: Mechanisms of design-related failures. PACE 1986, 9:1166-1172.
179. Cameron J, Mond H, Ciddor G, et al. Stiffness of the distal tip of bipolar pacemaker leads. PACE 1990, 13:1915-1920.
180. Mugica J, Daubert JC, Lazarus B, et al. Is polyurethane lead insulation still controversial?. PACE 1992, 15:1967-1970.
181. Phillips R, Frey M, Martin RO Long-term performance of polyurethane pacing leads: Mechanisms of design-related failures. PACE 1986, 9:1166-1172.
182. Mond H, Sloman G The small tined pacemaker lead: Absence of dislodgement. PACE 1980, 3:171-177.
183. Kertes P, Mond H, Sloman G, et al. Comparison of lead complications with polyurethane tined, silicone rubber tined, and wedge tip leads: Clinical experience with 822 ventricular endo-cardial leads. PACE 1983, 6:957-962.
184. Stokes KB Recent advances in lead technology. New Perspectives in
185. Ormerod D, Walgren S, Berglund J, Heil R Design and evaluation of a low threshold porous tip lead with a mannitol coated screw-in tip ("Sweet Tip"). PACE 1988, 11:1784-1790.
186. Bisping HJ, Kreuzer J, Birkenheier H Three year clinical experience with a new endocardial screw-in lead with introduction protection for use in the atrium and ventricle. PACE 1980, 3:424-435.
187. Crossley GH, Brinkler JA, Reynolds D, et al. Steroid elution improves the stimulation threshold in an active-fixation atrial permanent pacing lead. Circulation 1995, 92:2935-2939.
188. Hidden-Lucet F, Halimi F, Gallais Y, et al. Low chronic pacing thresholds of steroid-eluting active-fixation ventricular pacemaker leads: A useful alternative to passive-fixation leads. PACE 2000, 23:1798-1800.
189. Mond H, Stokes KB The electrode-tissue interface: The revolutionary role of steroid elution. PACE 1992, 15:95-107.
190. Mond H, Stokes K, Helland J, et al. The porous titanium steroid eluting electrode: A double blind study assessing the stimulation threshold effects of steroid. PACE 1988, 11:214-219.
191. Mond H, Stokes KB The steroid-eluting electrode: A 10 year experience. PACE 1997, 19:1016-1020.
192. Kruse IM Long-term performance of endocardial leads with steroid-eluting electrodes. PACE 1986, 9:1217-1219.
193. Hua W, Mond H, Sparks P The clinical performance of three designs of atrial pacing leads from a single manufacturer: The value of steroid elution. Eur J Cardiac Pacing Electrophysiol 1996, 6:99-103.
194. Schuchert A, Hopf M, Kuck KH, et al. Chronic ventricular electrograms: Do steroid eluting leads differ from conventional leads?. PACE 1990, 13:1879.
195. Kay GN, Brinker JA, Kawanishi DT, et al. Risks of spontaneous injury and extraction of an active fixation pacemaker lead: report of the Accufix Multicenter Clinical Study and Worldwide Registry. Circulation 1999, 100:2344-2352.
196. Parsonnet V, Roelke M, Bernstein AD, Stern M Reduced frequency of retention wire fractures suggests that elective explantation of affected atrial leads is no longer indicated. PACE 2000, 23:380-383.
197. Lau C, Nishimura SC, Oxorn D, Goldman BS Is this the natural history of the retention wire? A case report. PACE 1997, 20:1373-1376.
198. Kao HL, Wang SS, Chen WJ, et al. Migration of a fractured retention wire in the pulmonary artery from an active fixation atrial lead. PACE 1995, 18:1966.
199. Tatou E, Lefex C, Reybet-Degat O, et al. Intrapulmonary artery and intrabronchial migration and extraction of a fragment of J-shaped atrial pacing catheter. PACE 1999, 22:1829-1830.
200. Saliba BC, Ardesia RJ, John RM, et al. Predictors of fracture in the Accufix atrial "J" lead. Am J Cardiol 1997, 80:229-231.
201. Kawanishi DT, Brinker JA, Reeves R, et al. Cumulative hazard analysis of J-wire fracture in the Accufix series of atrial permanent pacemaker leads. PACE 1998, 21:2322-2326.
202. Lloyd MA, Hayes D, Holmes DR Atrial J-pacing lead retention wire fracture: Radiographic assessment, incidence of fracture and clinical management. PACE 1995, 18:958-964.
203. Important Information about Telectronics Accufix and Encor Atrial "J" Leads. Accufix Research Institute, April 2005.